Factors used to assess efficacy and need for ongoing TNF inhibitor therapy*
| Response (mean) | |
|---|---|
| *n = 880 (online survey, US rheumatologists, April 2005). | |
| Respondents were asked to rank these on a scale of 1–8 from most important (1) to never important (8). | |
| Physician joint examination | 1.69 |
| Patient assessment of response | 1.88 |
| Drug tolerability | 2.04 |
| Physician global assessment | 2.14 |
| Radiographic assessments | 2.94 |
| Erythrocyte sedimentation rate or C-reactive protein | 3.18 |
| Functional outcome measures | 4.20 |
| Disease Activity Score (DAS) | 5.41 |